Characteristics | Number | |
---|---|---|
Patients | 29 | |
Age, median (range) | 76 (56–89) | |
<75 | ||
≥75 | ||
Gender | ||
male | 20 | |
female | 9 | |
PS | ||
0 | 2 | |
1 | 22 | |
2 | 5 | |
T-stage | ||
T2a | 18 | |
T2b | 2 | |
T3 | 9 | |
Location of the tumor 1 | ||
lower lobe | 11 | |
middle, upper lobe | 18 | |
Location of the tumor 2 | ||
near the pulmonary hilum | 8 | |
Peripheral | 21 | |
Pathology | ||
squamous carcinoma | 17 | |
adenocarcinoma | 12 | |
Dose (Gy), median (range) | 60 (48–60) | |
48Gy, 3Gy/f | 1 | |
50Gy, 5Gy/f | 3 | |
54Gy, 6Gy/f or 3Gy | 2 | |
60Gy, 3Gy/f | 2 | |
60Gy, 4Gy/f | 8 | |
60Gy, 5Gy/f | 10 | |
60Gy, 6Gy/f | 3 | |
BED (Gy), median (range) | 84 (67.2-90) | |
<80 Gy | 14 | |
≥80 Gy | 15 | |
Fraction size (Gy) | ||
3 | 7 | |
4 | 5 | |
5 | 15 | |
6 | 2 | |
Chemotherapy | ||
TS-1 | neoadjuvant | 1 |
concurrent | 1 | |
adjuvant | 1 | |
UFT | concurrent | 1 |